<- Go Home
Ikena Oncology, Inc.
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd.
Market Cap
$69.0M
Volume
9.8K
Cash and Equivalents
$58.3M
EBITDA
-$41.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$29.9M
Profit Margin
N/A
52 Week High
$23.28
52 Week Low
$11.65
Dividend
N/A
Price / Book Value
0.60
Price / Earnings
-2.24
Price / Tangible Book Value
0.60
Enterprise Value
-$21.0M
Enterprise Value / EBITDA
0.58
Operating Income
-$41.6M
Return on Equity
23.76%
Return on Assets
-18.32
Cash and Short Term Investments
$95.6M
Debt
$5.7M
Equity
$115.9M
Revenue
N/A
Unlevered FCF
-$22.7M
Sector
Pharmaceuticals
Category
N/A